Kunpeng Li

Kunpeng Li

Auto-generated profile, based on publicly available information

Kunpeng Li

Department of Rheumatology and Immunology, the First Medical Center, Chinese PLA General Hospital, Beijing, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2019 in BioMed Research International
Verified
Journal Article
Open access
PDF file
XJXiaojian Ji
Xiaojian Ji
YWYiwen Wang
Yiwen Wang
YMYingpei Ma
Yingpei Ma
ZHZhengyuan Hu
Zhengyuan Hu
SMSiliang Man
Siliang Man
FHFeng Huang
Feng Huang
Objectives. Ankylosing spondylitis (AS) is a chronic disease that decreases mobility, function, and quality of life. This study introduced the “Smart-phone SpondyloArthritis Management System” (SpAMS), an interactive mobile health (mHealth) tool designed for AS/spondyloarthritis (SpA) disease management and used SpAMS data to evaluate clinical characteristics of Chinese patients with AS. Methods. SpAMS integrates patient’s and physician’s portals in a smart phone application. The Chinese Ankylosing Spondylitis Prospective Imaging Cohort was launched using SpAMS in April 2016. Patient self-assessments were completed online at baseline and at every subsequent clinic visit. Physician-reported assessments and treatments were recorded by rheumatologists during each visit. Results. In total, 1201 patients with AS [mean (SD) age, 30.6 (8.7) years; male, 82.6%] were recruited. Mean (SD) disease duration was 8.4 (6.1) years. Past or current symptoms of acute anterior uveitis (AAU), psoriasis, and inflammatory bowel disease (IBD) were observed in 21.0%, 3.7%, and 9.4% of patients, respectively. AAU and IBD occurred significantly more in patients with symptom duration > 10 years. The most commonly used medications at baseline were nonsteroidal anti-inflammatory drugs (98.2%). Patients using tumour necrosis factor inhibitors accounted for 20.8%, and 66.4% of patients used conventional synthetic disease-modifying antirheumatic drugs. At baseline, 57.2% of patients had inactive disease (ID)/low disease activity (LDA); this rate significantly improved to 79.2% after a mean follow-up of 13.3 (5.9) months. Compared with relapsed patients, new achievers of ID/LDA underwent more online patient assessments (P < .001). Problems solved in SpAMS caused 29.1% of clinic visits to a tertiary hospital unnecessary. SpAMS saved an average of 5.3 hours and 327.4 RMB per person on traffic expenses; these expenses equalled 16% of the Chinese monthly disposable personal income. Conclusions. SpAMS is a time- and cost-saving disease management tool that can help patients with AS perform self-management and provide valuable data to clinicians.

4 November 2023 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
LCLin Chen
Lin Chen
JLJing Li
Jing Li
KLKunpeng Li
Kunpeng Li
JHJiang Hu
Jiang Hu
QLQingjie Li
Qingjie Li
LTLing-Long Tang
Ling-Long Tang

24 May 2024 in JMIR Research Protocols
Verified
Journal Article
Open access
AWAnan Wang
Anan Wang
YWYunong Wu
Yunong Wu
XJXiaojian Ji
Xiaojian Ji
XWXiangyang Wang
Xiangyang Wang
JHJiawen Hu
Jiawen Hu
TLTao Li
Tao Li
Background: Spondyloarthritis (SpA), a chronic inflammatory disorder, predominantly impacts the sacroiliac joints and spine, significantly escalating the risk of disability. SpA’s complexity, as evidenced by its diverse clinical presentations and symptoms that often mimic other diseases, presents substantial challenges in its accurate diagnosis and differentiation. This complexity becomes even more pronounced in nonspecialist health care environments due to limited resources, resulting in delayed referrals, increased misdiagnosis rates, and exacerbated disability outcomes for patients with SpA. The emergence of large language models (LLMs) in medical diagnostics introduces a revolutionary potential to overcome these diagnostic hurdles. Despite recent advancements in artificial intelligence and LLMs demonstrating effectiveness in diagnosing and treating various diseases, their application in SpA remains underdeveloped. Currently, there is a notable absence of SpA-specific LLMs and an established benchmark for assessing the performance of such models in this particular field. Objective: Our objective is to develop a foundational medical model, creating a comprehensive evaluation benchmark tailored to the essential medical knowledge of SpA and its unique diagnostic and treatment protocols. The model, post-pretraining, will be subject to further enhancement through supervised fine-tuning. It is projected to significantly aid physicians in SpA diagnosis and treatment, especially in settings with limited access to specialized care. Furthermore, this initiative is poised to promote early and accurate SpA detection at the primary care level, thereby diminishing the risks associated with delayed or incorrect diagnoses. Methods: A rigorous benchmark, comprising 222 meticulously formulated multiple-choice questions on SpA, will be established and developed. These questions will be extensively revised to ensure their suitability for accurately evaluating LLMs’ performance in real-world diagnostic and therapeutic scenarios. Our methodology involves selecting and refining top foundational models using public data sets. The best-performing model in our benchmark will undergo further training. Subsequently, more than 80,000 real-world inpatient and outpatient cases from hospitals will enhance LLM training, incorporating techniques such as supervised fine-tuning and low-rank adaptation. We will rigorously assess the models’ generated responses for accuracy and evaluate their reasoning processes using the metrics of fluency, relevance, completeness, and medical proficiency. Results: Development of the model is progressing, with significant enhancements anticipated by early 2024. The benchmark, along with the results of evaluations, is expected to be released in the second quarter of 2024. Conclusions: Our trained model aims to capitalize on the capabilities of LLMs in analyzing complex clinical data, thereby enabling precise detection, diagnosis, and treatment of SpA. This innovation is anticipated to play a vital role in diminishing the disabilities arising from delayed or incorrect SpA diagnoses. By promoting this model across diverse health care settings, we anticipate a significant improvement in SpA management, culminating in enhanced patient outcomes and a reduced overall burden of the disease. International Registered Report Identifier (IRRID): DERR1-10.2196/57001

22 January 2026 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
XJXiaojian Ji
Xiaojian Ji
ZLZhuofeng Li
Zhuofeng Li
LZLulu Zeng
Lulu Zeng
LHLidong Hu
Lidong Hu
YWYanyan Wang
Yanyan Wang
KLKunpeng Li
Kunpeng Li
Axial spondyloarthritis (axSpA) is an inflammatory disease marked by chronic low back pain, with a global average diagnostic delay of 6.7 years. Early diagnosis is crucial for improving prognosis and reducing disability rates, yet primary care physicians (PCPs) may find it challenging to ensure timely recognition and referrals. This study developed and validated Spondyloarthritis Agents (SpAgents), an early diagnostic system based on a multi-agent framework integrating large language models (LLMs) and imaging models. The SpAgents framework includes PlannerAgent, DataAgent, ToolAgent, and DoctorAgent, supported by long-term memory for dynamic knowledge updates. We enrolled 596 patients, dividing 545 from one hospital into a training dataset (n = 359) and a validation dataset (n = 186), along with an independent cohort of 51 patients from five additional hospitals for testing. SpAgents demonstrated strong diagnostic performance, achieving sensitivity of 0.8615 and specificity of 0.8000 during validation, and 0.9375 and 0.7368 during testing. SpAgents exhibited significantly higher sensitivity (0.9400) and accuracy (0.8600) than both PCPs and junior rheumatologists, with overall performance equivalent to that of senior rheumatologists. Under SpAgents-assisted diagnosis, both PCPs and junior rheumatologists showed marked improvements in sensitivity and accuracy. SpAgents effectively enhance early axSpA identification among PCPs, offering an innovative solution to reduce diagnostic delays.

15 December 2021 in Chinese Medical Journal
Verified
Journal Article
Open access
YWYuehua Wan
Yuehua Wan
JYJinshui Yang
Jinshui Yang
YZYurong Zhao
Yurong Zhao
JJJingyu Jin
Jingyu Jin
JZJian Zhu
Jian Zhu
JZJianglin Zhang
Jianglin Zhang
An abstract is unavailable. This article is available as a PDF only.

1 January 2023 in International Journal of Mental Health Promotion
Verified
Journal Article
Open access
PDF file
CXCuirong Xu
Cuirong Xu
HYHan Yan
Han Yan
DXDawei Xu
Dawei Xu
GCGuanjie Chen
Guanjie Chen
QXQian Xu
Qian Xu
JSJing Sun
Jing Sun
Objective: The purpose of this study was to evaluate the effectiveness of post-traumatic growth (PTG) model-based intervention to improve positive psychological traits in Chinese breast cancer patients. Design: A randomized control trial of a psychological group intervention based on PTG model. Methods: The Clinical Trial was registered on 17 August 2019 at Chinese Clinical Trials.gov with Registration number ChiCTR1900025264. A total of 92 patients with breast cancer were recruited. The participants were randomly assigned to the experimental group (n = 46) and the control group (n = 46). A six-session psychological group intervention based on PTG model was implemented in the experimental group, and a six-session health education was implemented in the control group. The outcomes were measured at baseline (pre-intervention), 3 weeks, 6 weeks after the intervention. The primary outcome was posttraumatic growth assessed by the Chinese version of the Post-Traumatic Growth Inventory (PTGI); Secondary outcomes included psychological resilience, family resilience, rumination, and self-disclosure. Results: A total of 87 patients with breast cancer completed this study, including 44 patients in the experimental group and 43 patients in the control group. There was no significant difference in baseline data of breast cancer patients between the two groups except for the treatment regimen (p > 0.05). The two groups were compared after the intervention; the interaction effects between the total scores of posttraumatic growth, family resilience, and self-disclosure and the time term were statistically significant (p < 0.05), indicating that the trend of change in total scores of post-traumatic growth, family resilience, and self-disclosure differed between the experimental and control groups over time, and the scores improved in the experimental group were significantly higher than those in the control group. The comparison of psychological resilience and total score of rumination at each time point was statistically significant (p < 0.05), indicating that group intervention based on the PTG model could improve the psychological recovery ability and rumination level of the experimental group. Conclusion: The psychological group intervention based on the PTG model significantly improved post-traumatic growth, family resilience, and self-disclosure in patients with breast cancer. However, the impact on psychological resilience and rumination was relatively small. Long-term intervention is needed to further test the effect of the PTG model on psychological resilience and rumination.